|
Patent landscape, scope, and claims summary: |
United States Patent 4,530,901 (Recombinant DNA for Interferon-α) claims and US patent landscape analysis
US Patent 4,530,901 is drafted as a broad, early-generation recombinant DNA estate around: (i) a recombinant DNA molecule assembled outside living cells from heterologous DNA segments that can replicate or be maintained in a host; (ii) DNA encoding interferon-α polypeptides; (iii) hybridization-defined variants of specific interferon-α DNA inserts; and (iv) operable linkage to generic prokaryotic and viral expression control sequences, with corresponding coverage to transformed hosts and methods of producing interferon-α polypeptides. The claims are structurally broad enough to read across multiple interferon-α insert variants and multiple cloning vehicles and expression systems, but the practical enforceable scope is constrained by how specific the referenced deposits/constructs are and by the validity risks typical for foundational recombinant DNA claims in the US.
Claim architecture (what the patent actually covers)
The asserted claim set (1, 2-4, 5-8, 9-18) falls into five coverage buckets:
-
Recombinant DNA molecule (claim 1 and dependent claims 2-4, 17)
- Core definition: recombinant DNA assembled end-to-end outside living cells, containing segments from different genomes, capable of infecting and being maintained in a host (or “progeny thereof”).
- Payload: DNA sequences selected from
(a) specific “insert” constructs listed by plasmid backbone + restriction site + interferon-α allele (Z‑pBR322(Pst)/HcIF‑2h, Z‑pBR322(Pst)/HcIF‑SN35, Z‑pBR322(Pst)/HcIF‑SN42, Z‑pKT287(Pst)/HcIF‑2h‑AH6, and also HcIF‑4c under claim 5/8);
(b) hybridizing sequences to any of those inserts that code for an IFN‑α polypeptide;
(c) sequences encoding IFN‑α polypeptides as coded by expression from the foregoing sequences/inserts.
- Expression linkage: “operatively linked” to an expression control sequence.
- Vector/architecture refinements: cloning vehicles with restriction sites (claim 2), expression control sequence included in the vehicle (claim 3), and expression control systems enumerated (lac, trp, λ promoter/operator regions, fd coat control region, and “other” prokaryotic/eukaryotic/viral gene control sequences) (claim 4).
- Vehicle type: plasmids or phages (claim 17).
-
Transformed unicellular host (claims 5-8, 6-7, 15-16)
- Host claim mirrors the molecule payload and requires transformation with at least one recombinant DNA molecule.
- Specificity includes E. coli HB101 with particular constructs mapped to deposits (claim 7).
- Scope includes other hosts in dependent claims (microorganism in claim 16; broad host types in method claims).
-
Purified/isolated DNA (claim 8)
- “Substantially pure DNA sequence” limited to: the listed inserts, hybridizing IFN‑α coding sequences, and IFN‑α coding sequences encoding only a single polypeptide chain.
- This is a different enforceability lane than the recombinant construct, because it can target defendants that provide isolated DNA even if the full vector architecture differs.
-
Methods of producing IFN‑α (claims 9-14, 12-15)
- Steps: prepare recombinant DNA with operatively linked expression control; transform appropriate host; culture; collect polypeptide (claim 9).
- Variant method: culturing a transformed host and collecting polypeptide (claim 12).
- Host lists: broad in dependent claims (E. coli, Pseudomonas, Bacillus species, yeasts/fungi, animal and plant hosts, and human tissue cells) (claim 10, and claim 13 for the shorter method).
- Expression control lists are mirrored (claim 11, and claim 14).
-
Narrower dependencies tying structure to delivery formats (claims 2-4, 17-18)
- Vector restriction site insertion (claim 2) and operably linked expression control inserted into vehicle (claim 3).
- Method/molecule linkage: plasmids/phages in claim 18.
What patents protect recombinant DNA interferon‑α molecules like US 4,530,901 in the US?
US 4,530,901’s “coverage” should be treated as a foundational recombinant DNA and expression-enabling estate. The enforceable US landscape around this family historically clusters into three interacting layers:
-
DNA sequence and hybridization-defined IFN‑α constructs
- US 4,530,901 is explicitly drafted to include (i) the named inserts associated with particular plasmid backbones and interferon-α variants, (ii) hybridizing sequences that code for IFN‑α, and (iii) chains encoding IFN‑α products.
- This style tends to be mirrored across other early interferon gene cloning patents, where “hybridization” and “operatively linked” language recurs.
-
Expression system and host implementation claims
- Claim coverage extends to transformed hosts and broad expression systems by listing common promoters/operators (lac, trp, λ, fd coat control) and then sweeping to “other sequences” controlling gene expression in prokaryotic/eukaryotic cells and viruses.
-
Downstream product/formulation patents (not in this claim set)
- The claims you provided do not include formulation, dosing, device, or patient-treatment end-use claims, beyond the gene/protein production lane.
- In the US, interferon-α commercialization commonly faced additional patent layers on specific marketed drug forms, processes, and therapeutic regimens. Those are typically separate from gene-cloning patents.
How US 4,530,901’s claim language maps to other likely interferon‑α IP classes
- If a competitor practices recombinant IFN‑α production, they likely touch:
- a recombinant DNA claim (vector + insert + control sequence),
- a transformed host claim,
- and/or a method-of-production claim.
- If they instead focus on a different IFN‑α allele, different coding sequence boundaries, or different expression strategy, the “hybridize to” and “operatively linked to” elements in US 4,530,901 can still catch them unless their sequences fall outside the hybridization envelope and their expression control system falls outside the claim’s enumeration/scope construction.
Which IFN‑α sequences and recombinant constructs are explicitly claimed in US 4,530,901?
Explicit insert set (as recited in the claims you provided)
Two claim groups list overlapping, but not identical, insert enumerations:
Claim 1 insert group (core recombinant DNA molecule):
- Z‑pBR322(Pst)/HcIF‑2h (DSM 1700)
- Z‑pBR322(Pst)/HcIF‑SN35 (DSM 1701)
- Z‑pBR322(Pst)/HcIF‑SN42 (DSM 1702)
- Z‑pKT287(Pst)/HcIF‑2h‑AH6 (DSM 1703)
Claim 5 insert group (transformed host):
- Z‑pBR322(Pst)/HcIF‑4c (DSM 1699)
- plus the same set as claim 1: HcIF‑2h (DSM 1700), SN35 (DSM 1701), SN42 (DSM 1702), and 2h‑AH6 (DSM 1703)
Claim 8 isolated DNA group:
- same set as claim 5: includes HcIF‑4c (DSM 1699) and the others through DSM 1703.
What the hybridization language does (and what it does not)
- “DNA sequences which hybridize to any of the foregoing DNA inserts and which code on expression for a polypeptide of the IFN‑α type” expands coverage beyond the named inserts.
- It does not automatically cover any IFN‑α sequence. It requires hybridization to those inserts and coding for an IFN‑α polypeptide in expression.
- The hybridization constraint is often the litigation pressure point because it depends on the specification’s hybridization conditions and the closeness of the competitor’s nucleic acid to the patented reference sequences.
Single-chain constraint for isolated DNA (claim 8)
- Claim 8 restricts isolated DNA coding “for only a single polypeptide chain.”
- That can matter where a competitor uses alternative processing signals or constructs that yield different chained products or includes segments that could be interpreted as multiple polypeptide chains.
What expression control elements does US 4,530,901 claim for recombinant IFN‑α production?
Enumerated expression systems
US 4,530,901’s claim 4 and method claims 11/14 enumerate a standard set of expression-control concepts:
- lac system
- trp system
- major operator and promoter regions of phage λ
- control region of fd coat protein
- “other sequences which control the expression of genes of prokaryotic or eukaryotic cells and their viruses.”
Vector architecture constraints
- Claim 2: cloning vehicle with at least one restriction endonuclease recognition site; insertion at one site or between two sites.
- Claim 3: expression control sequence is also inserted into the cloning vehicle.
Scope implication for design-arounds
- A competitor that uses an expression system not captured by the construction of “operatively linked” and the claim’s control-sequence category might still fall under the “other sequences” catch-all. Practically, early recombinant DNA patents often face broad claim construction at the “control sequence” level unless the intrinsic record narrows it.
How broad are the host and method claims, and where do they likely face validity or construction risks?
Host breadth (claims 5-7, 10, 13, 15-16)
- Claim 7 explicitly lists E. coli HB101 hosting specific plasmids mapped to DSM deposits.
- Method claims list broad host categories: E. coli, Pseudomonas, Bacillus species, yeasts/fungi, animal/plant hosts, and human tissue cells (claims 10, 13).
What “infect some host and be maintained therein” means in practice
- The claims are written with hybrid infective/maintenance language that can read on phage or viral-host systems, but also on plasmid-based maintenance depending on claim interpretation.
- Claim 17 and 18 narrow “molecule selected from plasmids and phages,” which is consistent with this structural choice.
Likely pressure points (critical claim analysis)
Even without reviewing prosecution history or the full specification, several features of this claim set are structurally broad and typical for early recombinant DNA filings:
- Hybridization-defined coverage can be challenged if the hybridization criteria are not sufficiently defined in the intrinsic record to set boundaries.
- “Other sequences” catch-all around expression control systems can create indefiniteness or overbreadth risk, though it also increases enforceable breadth.
- Functional language like “capacity to infect some host and to be maintained therein” can be construed broadly, but defendants often argue the claim is not tied to the exact intended mechanism of maintenance.
These are the areas where litigation outcomes usually turn: claim construction first (what parameters bind “hybridize”), then validity under early biotech doctrines (enablement/adequacy of written description historically), and then infringement mapping to actual constructs.
What generic entry risks exist for recombinant IFN‑α gene patents like US 4,530,901?
This patent is a gene-construct and production method claim, not a small-molecule “generic drug product” claim. The relevant “entry risk” for competitors is commercial and regulatory process risk:
- If a biosimilar or follow-on biologic is produced via recombinant IFN‑α expression constructs that fall within the claim scope (sequence identity/hybridization, vector/control systems), infringement risk exists regardless of the final formulated drug.
- If the competitor uses different IFN‑α coding sequences, different maturation strategy, and different hybridization relationships, they may avoid the sequence core.
- If they use alternative promoters not captured by the control-sequence claim construction, they can potentially avoid the “operatively linked expression control sequence” element, though “other sequences” language reduces the safe haven.
In licensing terms, this patent tends to support:
- cross-licensing of recombinant DNA enabling technology,
- or freedom-to-operate positions conditional on sequence and expression-control design.
How does US 4,530,901 compare with later interferon‑α recombinant DNA patent estates?
Common evolution in later estates
Later patents in this field typically narrow and monetize one or more of:
- specific IFN‑α subtypes with exact nucleotide sequences and processing architectures,
- improved promoters and expression vectors,
- specific host strains and fermentation process parameters,
- and sometimes specific purified polypeptide attributes.
US 4,530,901 is comparatively broad:
- it includes hybridization-defined variants to named inserts,
- it includes broad host categories,
- it includes widely used bacterial and viral promoter systems.
Practical comparison summary
- Compared with narrower later patents, US 4,530,901 is higher-risk for competitors unless they can prove non-hybridizing sequence divergence and non-covered expression control architecture.
- Compared with broader families, it is limited to IFN‑α coding sequences and the recombinant DNA assembly/host maintenance framework.
Patent term and exclusivity: when does US 4,530,901 lose exclusivity?
US 4,530,901 is a US utility patent with a base term running from the effective filing date (adjusted for patent term adjustments). The exact statutory expiration date depends on:
- the application filing date,
- whether terminal disclaimers exist,
- and patent term adjustment/history.
No filing date, PTA, or disclaimer data were provided in the input. Without those, an expiration date cannot be stated accurately.
Orange Book status of US 4,530,901: is it listed for any FDA-approved product?
US 4,530,901 is a recombinant DNA patent that may or may not be listed in the FDA Orange Book, depending on whether it is tied to an FDA-approved drug product NDA/BLA and whether the patent holder listed it. No Orange Book listing identifiers (drug name, application number, listed patent number mapping) were provided in the input. Without those, Orange Book status cannot be determined from the information given.
Key claim-by-claim infringement mapping checklist (how competitors would analyze US 4,530,901)
Claim 1 DNA molecule test
A potential infringer would focus on:
- Recombinant assembly outside living cells
- Heterologous segments from different genomes joined end-to-end
- Capacity to infect and be maintained in a host
- Insert coverage: does the IFN‑α coding DNA match one of the named inserts or hybridize to them?
- Expression control linkage: is the insert operatively linked to a control sequence falling within the lac/trp/λ/fd category or “other sequences” within claim scope?
Claim 5 host test
- Host transformed with at least one recombinant DNA molecule meeting claim 1 constraints.
Claim 7 E. coli HB101 mapping
- If a competitor uses E. coli HB101 with a substantially similar plasmid insert/control structure, the claim is more direct.
Claim 8 isolated DNA test
- Does the competitor sell, distribute, or use substantially pure IFN‑α DNA that codes for only a single polypeptide chain?
Claims 9/12 method test
- Practical production mapping: transform, culture, collect polypeptide with the claimed recombinant system.
Key Takeaways
- US 4,530,901 claims a broad recombinant DNA estate for IFN‑α: named interferon-α insert constructs plus hybridization-defined variants, operatively linked to enumerated common expression-control systems and hosted in plasmid/phage-based delivery constructs.
- The claim set spans DNA molecule, transformed host, substantially pure DNA, and methods of producing IFN‑α polypeptide, with broad host type coverage in method dependents.
- Enforceability and design-around strategy typically hinge on the hybridization boundary to the named inserts and the construction of the “expression control sequence” element, not on the final drug formulation.
- Expiration timing, Orange Book linkage, and any US litigation history cannot be derived from the provided input.
FAQs
1. What does “hybridize to” cover in recombinant DNA IFN‑α claims like US 4,530,901?
Hybridization-defined language extends coverage beyond the exact named inserts to sequences that hybridize under the patent’s defined criteria and code for an IFN‑α polypeptide on expression.
2. Can using a different interferon‑α subtype avoid infringement of US 4,530,901?
Potentially, if the competitor’s coding sequence does not hybridize to the named inserts and does not fall within the claim’s IFN‑α coding scope as interpreted.
3. Does US 4,530,901 cover both plasmids and phages?
Yes. Claims 17 and 18 explicitly select plasmids and phages as molecule types for the covered recombinant DNA and methods.
4. Are transformed host claims broader than method-of-production claims in US 4,530,901?
The host claims cover transformation with the recombinant molecule; method claims add the production steps (culture and collection). Both require the recombinant DNA to meet the same payload and control linkage elements.
5. Does US 4,530,901 claim final interferon‑α drug dosing or formulations?
No. The provided claims target recombinant DNA, transformed hosts, isolated DNA, and production methods for the IFN‑α polypeptide, not therapeutic regimen or dosage-form compositions.
References
- United States Patent 4,530,901, “Recombinant DNA molecule and method for producing interferon-α,” claims text provided in prompt.
More… ↓
⤷ Start Trial
|
